Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
News Category Global Banking & Finance Reviews Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing MELBOURNE, Australia, Jan. 21, 2021 — Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company...
Source: globalbankingandfinance.com